Pharmanutra Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	131.69	115.5	100.2	82.72	68.11
Other Revenue	0.47	0.65	0.5	0.34	0.03
Revenue	132.16	116.15	100.71	83.06	68.14
Revenue Growth (YoY)	13.78%	15.33%	21.24%	21.89%	20.04%
Cost of Revenue	65.37	56.91	52.09	41.14	35.99
Gross Profit	66.79	59.24	48.62	41.92	32.15
Selling, General & Admin	32.71	26.67	22.55	17.19	12.12
Other Operating Expenses	1.41	1.81	0.43	0.34	0.34
Operating Expenses	37.69	31.88	25.6	18.84	13.86
Operating Income	29.1	27.36	23.02	23.07	18.3
Interest Expense	-0.66	-1.06	-0.8	-0.06	-0.02
Interest & Investment Income	0.52	0.68	0.32	0.13	0.15
Currency Exchange Gain (Loss)	-0.08	-0.04	0.08	-0.03	-
Other Non Operating Income (Expenses)	1.64	0.77	1.17	0.34	0.4
EBT Excluding Unusual Items	30.52	27.71	23.79	23.45	18.83
Gain (Loss) on Sale of Assets	-0	-0.27	-0.03	-0.03	-0.02
Legal Settlements	-0.33	-0.27	-0.5	-	-
Pretax Income	30.19	27.16	23.26	23.42	18.81
Income Tax Expense	10.27	10.61	10.43	8.37	5.04
Earnings From Continuing Operations	19.92	16.55	12.83	15.05	13.77
Minority Interest in Earnings	0.09	0.06	-	-	-
Net Income	20	16.61	12.83	15.05	13.77
Net Income to Common	20	16.61	12.83	15.05	13.77
Net Income Growth	20.44%	29.43%	-14.73%	9.27%	-2.14%
Shares Outstanding (Basic)	10	10	10	10	10
Shares Outstanding (Diluted)	10	10	10	10	10
Shares Change (YoY)	-0.16%	-0.67%	-0.05%	-0.09%	-
EPS (Basic)	2.09	1.73	1.33	1.56	1.42
EPS (Diluted)	2.09	1.73	1.33	1.56	1.42
EPS Growth	20.63%	30.29%	-14.69%	9.37%	-2.13%
Free Cash Flow	16.43	16.17	-1.16	-8.69	15.43
Free Cash Flow Per Share	1.71	1.68	-0.12	-0.90	1.59
Dividend Per Share	1.200	1.000	0.850	0.800	0.710
Dividend Growth	20.00%	17.65%	6.25%	12.68%	5.97%
Gross Margin	50.54%	51.00%	48.28%	50.47%	47.18%
Operating Margin	22.02%	23.55%	22.86%	27.78%	26.85%
Profit Margin	15.14%	14.30%	12.74%	18.12%	20.21%
Free Cash Flow Margin	12.43%	13.92%	-1.15%	-10.46%	22.64%
EBITDA	31.82	30.87	25.44	24.22	19.3
EBITDA Margin	24.08%	26.58%	25.26%	29.16%	28.33%
D&A For EBITDA	2.72	3.51	2.42	1.15	1.01
EBIT	29.1	27.36	23.02	23.07	18.3
EBIT Margin	22.02%	23.55%	22.86%	27.78%	26.85%
Effective Tax Rate	34.03%	39.06%	44.83%	35.74%	26.78%
Revenue as Reported	133.97	116.91	101.96	83.39	68.84

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.